Onconetix, Inc. Announces 1-for-40 Reverse Stock Split
CINCINNATI, Ohio -- Onconetix, Inc. (NASDAQ: ONCO) has announced a 1-for-40 reverse stock split, a strategic move intended to boost its stock price. This change will take effect at 12:01 a.m. Eastern Time on the upcoming Tuesday. It’s a significant milestone for Onconetix, especially after receiving approval from shareholders during their 2024 annual meeting.
Highlights from the Annual Meeting of Stockholders
The annual meeting held on a recent Tuesday saw unanimous support from Onconetix's shareholders for all proposals presented. Here are some key takeaways:
1) Timothy Ramdeen and Ajit Singh were elected as Class III directors for the next three years;
2) Major amendments to the Company’s 2022 Equity Incentive Plan were approved, increasing the total shares from 3,150,000 to an impressive 58,000,000;
3) The Board was given discretion for a reverse stock split ranging from 1-for-30 to 1-for-60 shares;
4) A green light was given for issuing up to 5,709,935 shares of common stock when converting the Series A Preferred Stock;
5) Approval was granted for issuing 269,672,900 shares concerning the Series B Preferred Stock, showcasing Onconetix’s active management of its financing strategies;
6) Further endorsement of additional shares resulting from compensation arrangements in the Company’s market offerings was made;
7) EisnerAmper LLP was ratified as the independent registered public accounting firm for the upcoming fiscal year.
The Significance of the Reverse Stock Split
By implementing the reverse stock split, Onconetix aims to elevate its share price to meet Nasdaq's minimum requirement of $4.00 for continued market presence. As a result of this split, the total number of outstanding shares will significantly decrease, which will in turn increase their individual market value while keeping the overall par value intact.
Specifically, the Company expects to reduce approximately 30.2 million shares down to around 755,000 shares after the split. This strategic move is intended to strengthen its market position and enhance attractiveness to potential investors. For those holding shares, fractional shares will be rounded, and you’ll receive monetary compensation based on the last closing market price before the split.
Onconetix's Path Ahead
Onconetix is a leader in biotechnology, focusing on essential areas such as men’s health and oncology. The positive outcome from the recent annual meeting has boosted investor confidence in the Company as it navigates the complexities of the biotechnology sector. With innovative products like Proclarix for prostate cancer diagnostics and the FDA-approved ENTADFI medication, Onconetix is well-positioned for future growth in the industry.
Company Overview
Onconetix was established to create groundbreaking solutions for common health challenges and continues to develop its offerings in the competitive biotechnology landscape. The recent acquisition of Proteomedix enhances its portfolio, particularly as it prepares for the potential U.S. introduction of Proclarix, which had previously gained recognition in Europe. These strides reflect the Company’s commitment to transforming patient care.
Frequently Asked Questions
What is the purpose of the reverse stock split?
The reverse stock split is intended to raise the market price of Onconetix's shares in order to meet Nasdaq's listing requirements.
When will the reverse stock split take place?
The reverse stock split will be effective on a specific Tuesday, at 12:01 a.m. Eastern Time.
How will the reverse stock split affect my shares?
For every 40 shares you currently hold, you will receive one share in return, leading to fewer shares owned but a higher price per share.
What was approved at the annual meeting of stockholders?
What does the future hold for Onconetix?
With strategic initiatives like the reverse stock split and its lineup of innovative products, Onconetix is focused on improving its market position and increasing shareholder value.
